Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205340 | 0.92 | HTR6 (1.00) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL5558903 | 0.92 | HTR6 (0.84) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL947048 | 0.86 | HTR6 (0.75) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL946875 | 0.84 | HTR6 (1.00) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL946247 | 0.83 | HTR6 (0.98) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL27617670 | 0.81 | HTR6 (0.68) | HTR6 | |
| SCHEMBL3211898 | 0.79 | HTR6 (1.00) | HTR6 | |
| SCHEMBL947477 | 0.78 | HTR6 (0.83) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| SCHEMBL3216224 | 0.78 | HTR6 (1.00) | HTR6CYP3A4CYP2D6ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL946339 | 0.78 | HTR6 (0.83) | HTR6CYP3A4CYP2D6ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| CN-100378109-C | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LTD (IN) | 2008-04-02 | — | — | CN | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
| EP-1581538-B1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-02-28 | — | — | EP | disclosed |
| CN-1729197-A | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LTD (IN) | 2006-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | HTR6 9/4885CYP3A4 302/4885CYP2D6 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.